By Fineline Cube 
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European Hematology Association (EHA) Congress, showcasing advances in treating acute lymphoblastic leukemia (ALL), T-cell lymphoma (TCL), and other hematologic malignancies. The focus was on olverembatinib (HQP1351) and EED inhibitor APG – 5918.
Olverembatinib’s Efficacy in Ph+ ALL
Olverembatinib demonstrated robust efficacy across multiple treatment phases for Ph+ ALL patients. It was studied both as a combination therapy and as a bridge – to – transplant regimen. The drug was combined with various treatments including blinatumomab, VP chemotherapy, inotuzumab ozogamicin, and conventional chemotherapy, showing promising results.
APG-5918’s Promising Activity in TCL
APG – 5918 exhibited promising preclinical activity against TCL through PRC2 complex modulation. It induces tumor cell apoptosis and cell cycle arrest. Additionally, the drug showed synergistic anti – tumor effects when combined with chidamide.-Fineline Info & Tech